UroGen Pharma Future Growth
Future criteria checks 5/6
UroGen Pharma is forecast to grow earnings and revenue by 60.5% and 38.1% per annum respectively while EPS is expected to grow by 61.5% per annum.
Key information
60.5%
Earnings growth rate
61.5%
EPS growth rate
| Biotechs earnings growth | 21.1% |
| Revenue growth rate | 38.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 18 Apr 2024 |
Recent future growth updates
Recent updates
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09
UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18UroGen gets FDA nod for extending duration of Jelmyto admixture
Sep 28UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans
Mar 09We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate
Nov 04Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Invest In Growth?
Jun 14What Does The Future Hold For UroGen Pharma Ltd. (NASDAQ:URGN)? These Analysts Have Been Cutting Their Estimates
May 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 303 | 53 | N/A | N/A | 3 |
| 12/31/2025 | 181 | -62 | N/A | N/A | 5 |
| 12/31/2024 | 99 | -126 | N/A | N/A | 5 |
| 12/31/2023 | 83 | -102 | -77 | -76 | N/A |
| 9/30/2023 | 77 | -105 | -85 | -85 | N/A |
| 6/30/2023 | 73 | -109 | -86 | -85 | N/A |
| 3/31/2023 | 68 | -112 | -90 | -89 | N/A |
| 12/31/2022 | 64 | -110 | -88 | -88 | N/A |
| 9/30/2022 | 62 | -109 | -86 | -86 | N/A |
| 6/30/2022 | 58 | -114 | -87 | -87 | N/A |
| 3/31/2022 | 54 | -113 | -82 | -81 | N/A |
| 12/31/2021 | 48 | -111 | -86 | -85 | N/A |
| 9/30/2021 | 40 | -113 | -87 | -86 | N/A |
| 6/30/2021 | 32 | -111 | -94 | -93 | N/A |
| 3/31/2021 | 19 | -117 | -99 | -98 | N/A |
| 12/31/2020 | 12 | -128 | -107 | -106 | N/A |
| 9/30/2020 | 4 | -137 | -112 | -111 | N/A |
| 6/30/2020 | 0 | -130 | -99 | -98 | N/A |
| 3/31/2020 | 0 | -121 | -89 | -89 | N/A |
| 12/31/2019 | 0 | -105 | -71 | -71 | N/A |
| 9/30/2019 | 0 | -90 | -55 | -55 | N/A |
| 6/30/2019 | 0 | -88 | -52 | -52 | N/A |
| 3/31/2019 | 1 | -84 | -46 | -46 | N/A |
| 12/31/2018 | 1 | -76 | -38 | -37 | N/A |
| 9/30/2018 | 1 | -62 | -34 | -33 | N/A |
| 6/30/2018 | 9 | -42 | -22 | -21 | N/A |
| 3/31/2018 | 9 | -30 | -17 | -16 | N/A |
| 12/31/2017 | 8 | -21 | -10 | -10 | N/A |
| 9/30/2017 | 25 | 2 | N/A | 10 | N/A |
| 6/30/2017 | 18 | -7 | N/A | 4 | N/A |
| 3/31/2017 | 18 | -4 | N/A | 4 | N/A |
| 12/31/2016 | 18 | -4 | N/A | 4 | N/A |
| 9/30/2016 | N/A | -24 | N/A | -11 | N/A |
| 3/31/2016 | N/A | -16 | N/A | -8 | N/A |
| 12/31/2015 | N/A | -14 | N/A | -7 | N/A |
| 9/30/2015 | N/A | -7 | N/A | -7 | N/A |
| 12/31/2014 | N/A | -5 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: URGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: URGN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: URGN is expected to become profitable in the next 3 years.
Revenue vs Market: URGN's revenue (38.1% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: URGN's revenue (38.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if URGN's Return on Equity is forecast to be high in 3 years time